From molecule to medicine
We bring medicine to life for health systems across the globe
Orchid Pharma works across the entire pharmaceutical value chain, from original drug discovery and vertically integrated manufacturing to hospital stewardship, serving healthcare systems in 75+ countries.
Enmetazobactam: Orchids' New Chemical Entity (NCE)
30 years of serving healthcare systems across 75+ countries
.webp)
Our Integrated Capabilities
From molecule to medicine to stewardship
We address complex healthcare challenges by maintaining control over quality and cost through vertical integration. Our infrastructure supports global health by bringing advanced treatments to 75 countries.
Learn more
API Manufacturing
World-class ingredient production from the ground up
India's largest cephalosporin portfolio with backward integration from intermediates to finished APIs. One of only three global US FDA-approved sterile cephalosporin facilities.
Cephalosporins across all five generations
In-house 7-ACA manufacturing
50+ products with global regulatory approvals
Advanced Formulations
Essential medicines reaching underserved populations
Comprehensive formulations from next-generation antibiotics to essential therapies. Manufacturing breakthrough treatments through strategic global partnerships.
Injectable and oral cephalosporins
Wide portfolio across multiple therapeutic areas
100+ countries with active registrations
View Formulations
Novel Medicines
Breakthrough therapies for resistant infections
Pioneering anti-infective research addressing critical unmet needs. Enmetazobactam represents India's first New Chemical Entity to receive US FDA approval.
ORBLICEF™ (Cefepime–Enmetazobactam)
A novel β-lactam/β-lactamase inhibitor combination designed to combat ESBL-producing Enterobacterales, delivering enhanced microbiological coverage with robust clinical outcomes in severe infections.
ORTARO™ (Ceftaroline Fosamil)
A fifth-generation cephalosporin with potent anti-MRSA activity, offering reliable efficacy in Gram-positive infections along with a favorable safety and tolerability profile.
Cefiderocol
A last-line siderophore cephalosporin for the treatment of serious multidrug-resistant Gram-negative infections, including pathogens resistant to carbapenems.
Antimicrobial Stewardship
Partnering with hospitals to combat resistance
Evidence-based programs helping healthcare institutions reduce antimicrobial resistance through advanced products, expert guidance, and digital decision support.
Stewardship Framework Development
Stewardship Implementation
Clinical Audits and Gap Identification
Antimicrobial Prescribing Policy and Protocols
Capacity Building and Training
Learn About Our Programs
Global Trust and Scale
We build our operations around global regulatory standards, and ensure medicine reaches everyone who needs it.
Global reach across regulated and emerging markets
70+ Countries
Advancing pharmaceutical innovation since 1992
30+ Years
Global Cephalosporin Producer
Top 5
Our Partners in Global Health
We partner with leading pharmaceutical companies and global health organizations to expand access to critical medicines.
Manufacturing Excellence
Quality without compromise across four integrated facilities
State-of-the-art manufacturing sites spanning Chennai, Manesar, Keshwana, and Jammu. Full vertical integration from molecular synthesis to finished pharmaceutical products.
.webp)
Regulatory approvals
.png)
.png)
